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Background
Aim:
Final remarks:
Patients and Methods
Results
Table 1:Demographic  and clinical characteristics of epileptic patientsSixteen MTLE-HS patients and 24 healthy individuals were investigated. The study was approved by the Hospital Ethical Committee
and all individuals gave written informed consent in accordance with Declaration of Helsinki. Total RNA was isolated from serum using
the miRNeasy Mini kit (Qiagen) and reverse-transcribed with TaqMan miRNA Reverse Transcription Kit following the manufacturer's
protocol (Applied Biosystems, Inc., Foster City, CA). TaqMan miRNA assay included specific RT Primers and TaqMan Probes to quantify
mature microRNAs (has-miR-146a, has-miR-155). For normalization, RNU48 (hsa-miR-RNU48) was used. Each reaction was
performed in triplicate and the average Ct value was used in analysis. Relative expression values were calculated using the 2-ΔΔCt
method. Differences in ΔCt were evaluated using two-tailed Student’s t-test. Analyses were done with SPSS v.22 software and
significant levels were set at p<0.05.
Figure 1: miR-146a Relative expression in MTLE-HS and controls
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MiR-146a expression was 6 fold higher in MTLE-HS patients
Clinical and demographic characteristics Patients
Sex (F/M) 6/10
Age, years ± SD 42 ± 13
Epilepsy age of onset, years ± SD 16 ± 12
Febrile Seizures Antecedents 9
The induction of miRNA and their different effects may: - represent different cell responses during the several phases of epileptogenic process
- be the reflex of an abnormal function due to changes in the metabolic state of the cells
The role of miR-155 and miR-146a in epileleptogenic mechanism remains unknown and may depend on the availability of other molecules;
Two question are raised by these results:
Are miR-146a and /or miR-155 suitable biomarkers for MTLE-HS?
May these microRNAs be potential new therapeutic target?
Mesial Temporal Lobe Epilepsy with Hippocampal Sclerosis (MTLE-HS) is one of the most common pharmaco-resistant epileptic syndromes. Increasing evidence supports the involvement of
inflammatory processes in the deregulation of neurotransmission that characterizes epilepsy (Gorter et al. 2006). Studies in animal models demonstrated that after acute seizures a rapid induction of
cytokines and glial activation is involved in epileptic activity (Vezzani et al. 2011, Ravizza et al. 2006). It has been shown that these cytokines contribute to seizure-related hippocampal pathology, such
as neuronal death, reactive gliosis and mossy fiber sprouting. These findings are corroborated by observations showing that cytokines (e.g.: IL-1β and TNFα) and cytokines receptors are
overexpressed in patients’ brain tissue (Vezzani et al. 2008). Gene expression may be regulated by several factors including small non-coding RNA molecules - MicroRNAs (miRNA) that control
different biological process including immune system homeostasis and function. It has been showed that the activation of pro-inflammatory pathways via Toll Like Receptors, with the consequent
expression of cytokines such as IL-1β, leads to the induction of miRNAs such as miR-155 and miR-146a. MiR-155 has been associated with the suppression of negative regulators of inflammation and
upregulation of pro-inflammatory cytokines such as TNF-α whilst miR-146a acts in a feedback loop being a dominant negative regulator of inflammatory responses. Several evidences, both in patients
and animal models, have demonstrated an abnormal brain expression of these miRNA in MTLE (Jimenez-Mateos et al. 2013, Omran et al. 2012, Aronica et al. 2010) . It is known that miRNA
expression is very stable in biological fluids such as plasma or serum what makes them suitable biomarkers. Nevertheless the expression of these molecules in serum from MTLE patients is still poorly
addressed.
To characterize miR-146a and miR-155 expression in serum of MTLE patients.
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Figure 2: miR-155 Relative expression in MTLE-HS and controls
MTLE-HS patients had higher miR-155 expression than controls
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